These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37652161)

  • 21. Growth Trajectories in Stimulant-Treated Children Ages 6 to 12: An Electronic Medical Record Analysis.
    Biederman J; DiSalvo M; Green A; Hutt Vater C; Driscoll H; Faraone SV
    J Dev Behav Pediatr; 2023 Feb-Mar 01; 44(2):e80-e87. PubMed ID: 36750982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults - United States, 2016-2021.
    Danielson ML; Bohm MK; Newsome K; Claussen AH; Kaminski JW; Grosse SD; Siwakoti L; Arifkhanova A; Bitsko RH; Robinson LR
    MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(13):327-332. PubMed ID: 36995976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age of Onset, Duration, and Type of Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During Adolescence: A Multi-Cohort National Study.
    McCabe SE; Dickinson K; West BT; Wilens TE
    J Am Acad Child Adolesc Psychiatry; 2016 Jun; 55(6):479-86. PubMed ID: 27238066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal Trends in the Diagnosis of Attention-Deficit/Hyperactivity Disorder and Stimulant Use in Preschool Children on Medicaid.
    Davis DW; Feygin Y; Creel L; Williams PG; Lohr WD; Jones VF; Le J; Pasquenza N; Ghosal S; Jawad K; Yan X; Liu G; McKinley S
    J Pediatr; 2019 Apr; 207():185-191.e1. PubMed ID: 30545564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ADHD, stimulant treatment, and growth: a longitudinal study.
    Harstad EB; Weaver AL; Katusic SK; Colligan RC; Kumar S; Chan E; Voigt RG; Barbaresi WJ
    Pediatrics; 2014 Oct; 134(4):e935-44. PubMed ID: 25180281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.
    Betts KA; Sikirica V; Hodgkins P; Zhou Z; Xie J; DeLeon A; Erder MH; Wu EQ
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):260-8. PubMed ID: 24839998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
    Barner JC; Khoza S; Oladapo A
    Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design.
    Raman SR; Marshall SW; Haynes K; Gaynes BN; Naftel AJ; Stürmer T
    Inj Prev; 2013 Jun; 19(3):164-70. PubMed ID: 23143347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initiation of oral contraceptives and changes in blood pressure and body mass index in healthy adolescents.
    Kharbanda EO; Parker ED; Sinaiko AR; Daley MF; Margolis KL; Becker M; Sherwood NE; Magid DJ; O'Connor PJ
    J Pediatr; 2014 Nov; 165(5):1029-33. PubMed ID: 25189822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Banaschewski T; Johnson M; Nagy P; Otero IH; Soutullo CA; Yan B; Zuddas A; Coghill DR
    CNS Drugs; 2018 May; 32(5):455-467. PubMed ID: 29790103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
    Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
    Blader JC; Pliszka SR; Kafantaris V; Foley CA; Crowell JA; Carlson GA; Sauder CL; Margulies DM; Sinha C; Sverd J; Matthews TL; Bailey BY; Daviss WB
    J Am Acad Child Adolesc Psychiatry; 2013 Dec; 52(12):1281-93. PubMed ID: 24290461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization.
    Blader JC; Pliszka SR; Kafantaris V; Foley CA; Carlson GA; Crowell JA; Bailey BY; Sauder C; Daviss WB; Sinha C; Matthews TL; Margulies DM
    J Am Acad Child Adolesc Psychiatry; 2021 Feb; 60(2):236-251. PubMed ID: 32007604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of baseline and post-concussion ImPACT test scores in young athletes with stimulant-treated and untreated ADHD.
    Gardner RM; Yengo-Kahn A; Bonfield CM; Solomon GS
    Phys Sportsmed; 2017 Feb; 45(1):1-10. PubMed ID: 27736285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG; Perrin JM; Shelley-Abrahamson R; Wilens TE
    J Am Acad Child Adolesc Psychiatry; 2011 Oct; 50(10):978-90. PubMed ID: 21961773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physician perceptions of the use of medications for attention deficit hyperactivity disorder.
    Stockl KM; Hughes TE; Jarrar MA; Secnik K; Perwien AR
    J Manag Care Pharm; 2003; 9(5):416-23. PubMed ID: 14613439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attention deficit hyperactivity disorder medications and BMI trajectories: The role of medication type, sex and age.
    Gurka MJ; Siddiqi SU; Filipp SL; Mercado R; Thompson LA; Janicke DM; Shenkman EA
    Pediatr Obes; 2021 Apr; 16(4):e12738. PubMed ID: 33064373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of prescription stimulant for Attention Deficit Hyperactivity Disorder in Aboriginal children and adolescents: a linked data cohort study.
    Ghosh M; Holman CD; Preen DB
    BMC Pharmacol Toxicol; 2015 Dec; 16():35. PubMed ID: 26646429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder.
    Biederman J; Seidman LJ; Petty CR; Fried R; Doyle AE; Cohen DR; Kenealy DC; Faraone SV
    J Clin Psychiatry; 2008 Jul; 69(7):1150-6. PubMed ID: 18517288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose Adjustment of Stimulants for Children with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review of the Impact of Exceeding Recommended Doses.
    Ross L; Sapre V; Stanislaus C; Poulton AS
    CNS Drugs; 2020 Jun; 34(6):643-649. PubMed ID: 32300972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.